Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles

Journal of Virological Methods

Volumn 169, Issue 2, 2010, Pages 259-268

  Mandell, Robert B ^a   Koukuntla, Ramesh ^a   Mogler, Laura J K ^a   Carzoli, Andrea K ^a   Holbrook, Michael R ^b   Martin, Brian K ^c   Vahanian, Nicholas ^a,c   Link, Charles J ^a,c   Flick, Ramon ^a  

^a BioProtection Systems Corporation   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NEWLINK GENETICS   (United States)

Author keywords

Rift Valley fever virus; Suspension cells; Vaccine production; Virus like particles

Indexed keywords

RIFT VALLEY FEVER VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL ADHESION; CELL STRAIN HEK293; CELL SUSPENSION; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFICACY; FEMALE; INSECT CELL CULTURE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SURVIVAL RATE; TRANSIENT TRANSFECTION; VACCINATION; VACCINE PRODUCTION; VIRUS PARTICLE; WESTERN BLOTTING;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; RATS; RATS, INBRED WF; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SPODOPTERA; SURVIVAL ANALYSIS; VACCINES, VIROSOME; VIRAL VACCINES;

ARTHROPODA; HEXAPODA; MAMMALIA; RIFT VALLEY FEVER VIRUS;

EID: 77957018395     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.07.015     Document Type: Article

References (65)

1. Anderson G.W., Peters C.J. Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb. Pathog. 1988, 5:241-250.
2. Anderson G.W., Rosebrock J.A., Johnson A.J., Jennings G.B., Peters C.J. Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance. Am. J. Trop. Med. Hyg. 1991, 44:475-480.
3. Anderson G.W., Slone T.W., Peters C.J. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb. Pathog. 1987, 2:283-293.
4. Bird B.H., Albarino C.G., Hartman A.L., Erickson B.R., Ksiazek T.G., Nichol S.T. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 2008, 82:2681-2691.
5. Bird B.H., Albarino C.G., Nichol S.T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007, 362:10-15.
6. Bird B.H., Ksiazek T.G., Nichol S.T., Maclachlan N.J. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 2009, 234:883-893.
7. Bouloy M., Flick R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res. 2009.
8. Digital Image Processing: An Algorithmic Introduction Using Java 2008, Springer-Verlag, New York. W. Burger, M.J. Burge (Eds.).
9. Capua I., Cattoli G., Marangon S. DIVA-a vaccination strategy enabling the detection of field exposure to avian influenza. Dev. Biol. (Basel) 2004, 119:229-233.
10. Collett M.S., Keegan K., Hu S.-L. Protective subunit immunogens to Rift Valley fever virus from bacteria and recombinant vaccinia virus. The Biology of Negative Strand Viruses 1987, 321-329. Elsevier, New York. B. Mahy, D. Kolakofsky (Eds.).
11. Collett M.S., Purchio A.F., Keegan K., Frazier S., Hays W., Anderson D.K., Parker M.D., Schmaljohn C., Schmidt J., Dalrymple J.M. Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology 1985, 144:228-245.
12. Dalrymple J.M., Hasty S.E., Kakach L.T., Collett M.S. Mapping protective determinants of Rift Valley fever virus using recombinant vaccinia viruses. Vaccines '89 1989, 371-375. Cold Spring Harbor Laboratory, New York. R.A. Lerner, H. Ginsberg, R. Chanock, F. Brown (Eds.).
13. de Boer S.M., Kortekaas J., Antonis A.F., Kant J., van Oploo J.L., Rottier P.J., Moormann R.J., Bosch B.J. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010.
14. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173:3148-3154.
15. Flick R., Bouloy M. Rift Valley fever virus. Curr. Mol. Med. 2005, 5:827-834.
16. Fontenille D., Traore-Lamizana M., Diallo M., Thonnon J., Digoutte J.P., Zeller H.G. New vectors of Rift Valley fever in West Africa. Emerg. Infect. Dis. 1998, 4:289-293.
17. Garcea R.L., Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol. 2004, 15:513-517.
18. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 2004, 10:S110-S121.
19. Gerdes G.H. Rift Valley fever. Rev. Sci. Tech. 2004, 23:613-623.
20. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40:60-65.
21. Habjan M., Penski N., Wagner V., Spiegel M., Overby A.K., Kochs G., Huiskonen J.T., Weber F. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 2009, 385:400-408.
22. Harrison R.L., Jarvis D.L. Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce " mammalianized" recombinant glycoproteins. Adv. Virus Res. 2006, 68:159-191.
23. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev. Vaccines 2009, 8:435-445.
24. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J. Immunol. 2007, 178:2361-2369.
25. Hunt I. From gene to protein: a review of new and enabling technologies for multi-parallel protein expression. Protein Expr. Purif. 2005, 40:1-22.
26. Ikegami T., Makino S. Rift valley fever vaccines. Vaccine 2009, 27(Suppl. 4):D69-D72.
27. Kasari T.R., Carr D.A., Lynn T.V., Weaver J.T. Evaluation of pathways for release of Rift Valley fever virus into domestic ruminant livestock, ruminant wildlife, and human populations in the continental United States. J. Am. Vet. Med. Assoc. 2008, 232:514-529.
28. Kozak M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 1984, 12:857-872.
29. Kozak M. Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo. Nature 1984, 308:241-246.
30. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987, 15:8125-8148.
31. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 2002, 299:1-34.
32. Lagerqvist N., Naslund J., Lundkvist A., Bouloy M., Ahlm C., Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol. J. 2009, 6:6.
33. Liu L., Celma C.C., Roy P. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol. J. 2008, 5:82.
34. Mandell R.B., Flick R. Rift Valley fever virus - an unrecognized emerging threat?. Human Vaccines 2010, 6(7).
35. Mandell R.B., Koukuntla R., Mogler L.J., Carzoli A.K., Freiberg A.N., Holbrook M.R., Martin B.K., Staplin W.R., Vahanian N.N., Link C.J., Flick R. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2010, 397:187-198.
36. Maranga L., Cruz P.E., Aunins J.G., Carrondo M.J. Production of core and virus-like particles with baculovirus infected insect cells. Adv. Biochem. Eng. Biotechnol. 2002, 74:183-206.
37. Meegan J.M. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies. Trans. R. Soc. Trop. Med. Hyg. 1979, 73:618-623.
38. Monie A., Hung C.F., Roden R., Wu T.C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008, 2:97-105.
39. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6753-6758.
40. Nallet S., Amacker M., Westerfeld N., Baldi L., Konig I., Hacker D.L., Zaborosch C., Zurbriggen R., Wurm F.M. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells. Vaccine 2009, 27:6415-6419.
41. Naslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., Weber F., Bucht G. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009, 385:409-415.
42. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11:438-444.
43. Overby A.K., Popov V., Neve E.P., Pettersson R.F. Generation and analysis of infectious virus-like particles of uukuniemi virus (Bunyaviridae): a useful system for studying bunyaviral packaging and budding. J. Virol. 2006, 80:10428-10435.
44. Paillet C., Forno G., Kratje R., Etcheverrigaray M. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine 2009, 27:6464-6467.
45. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 2000, 16:273-282.
46. Pillay S., Meyers A., Williamson A.L., Rybicki E.P. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol. Prog. 2009, 25:1153-1160.
47. Roy P., Noad R. Virus-like Particles as a Vaccine Delivery System: Myths and Facts 2008, Landes Bioscience/Springer Science, Austin/New York.
48. Savellini G., Di Genova G., Terrosi C., Di Bonito P., Giorgi C., Valentini M., Docquier J.D., Cusi M.G. Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. Virology 2008, 375:521-528.
49. Schirmbeck R., Bohm W., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996, 39:111-119.
50. Schmaljohn C.S., Parker M.D., Ennis W.H., Dalrymple J.M., Collett M.S., Suzich J.A., Schmaljohn A.L. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989, 170:184-192.
51. Shi X., Goli J., Clark G., Brauburger K., Elliott R.M. Functional analysis of the Bunyamwera Orthobunyavirus Gc glycoprotein. J. Gen. Virol. 2009.
52. Shi X., Jarvis D.L. Protein N-glycosylation in the baculovirus-insect cell system. Curr. Drug Targets 2007, 8:1116-1125.
53. Shi X., Kohl A., Leonard V.H., Li P., McLees A., Elliott R.M. Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis. J. Virol. 2006, 80:8089-8099.
54. Shi X., Kohl A., Li P., Elliott R.M. Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis. J. Virol. 2007, 81:10151-10160.
55. Spik K., Shurtleff A., McElroy A.K., Guttieri M.C., Hooper J.W., SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006, 24:4657-4666.
56. Suzich J.A., Kakach L.T., Collett M.S. Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment. J. Virol. 1990, 64:1549-1555.
57. Swanepoel R., Coetzer J.A.W. Rift Valley fever. Infectious Diseases of Livestock with Special Reference to South Africa 2003, Oxford University Press Southern Africa, Cape Town. J.A.W. Coetzer, R.C. Tustin (Eds.).
58. Turell M.J., Dohm D.J., Mores C.N., Terracina L., Wallette D.L., Hribar L.J., Pecor J.E., Blow J.A. Potential for North American mosquitoes to transmit Rift Valley fever virus. J. Am. Mosq. Control Assoc. 2008, 24:502-507.
59. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006, 24:7181-7189.
60. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., Aman M.J., Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15889-15894.
61. Warnock J.N., Al-Rubeai M. Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol. Appl. Biochem. 2006, 45:1-12.
62. Warnock J.N., Merten O.W., Al-Rubeai M. Cell culture processes for the production of viral vectors for gene therapy purposes. Cytotechnology 2006, 50:141-162.
63. Won S., Ikegami T., Peters C.J., Makino S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J. Virol. 2006, 80:8274-8278.
64. Wu C.Y., Yeh Y.C., Yang Y.C., Chou C., Liu M.T., Wu H.S., Chan J.T., Hsiao P.W. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010, 5:e9784.
65. Wurm F., Bernard A. Large-scale transient expression in mammalian cells for recombinant protein production. Curr. Opin. Biotechnol. 1999, 10:156-159.